Migration in Namibia and its association with HIV acquisition and treatment outcomes.
Adolescent
Adult
Anti-Retroviral Agents
/ therapeutic use
Cross-Sectional Studies
Emigration and Immigration
Family Characteristics
Female
HIV Infections
/ drug therapy
HIV-1
/ genetics
Humans
Male
Middle Aged
Namibia
/ epidemiology
Prevalence
Self Report
Transients and Migrants
Treatment Outcome
Viral Load
Viremia
/ epidemiology
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
01
2021
accepted:
17
08
2021
entrez:
2
9
2021
pubmed:
3
9
2021
medline:
18
11
2021
Statut:
epublish
Résumé
In the 21st century, understanding how population migration impacts human health is critical. Namibia has high migration rates and HIV prevalence, but little is known about how these intersect. We examined the association between migration and HIV-related outcomes using data from the 2017 Namibia Population-based HIV Impact Assessment (NAMPHIA). The NAMPHIA survey selected a nationally representative sample of adults in 2017. All adults aged 15-64 years were invited to complete an interview and home-based HIV test. Recent infection (<130 days) was measured using HIV-1 LAg avidity combined with viral load (>1000 copies/mL) and antiretroviral analyte data. Awareness of HIV status and antiretroviral use were based on self-report and/or detectable antiretrovirals in blood. Viremia was defined as having a viral load ≥1000 copies/mL, including all participants in the denominator regardless of serostatus. We generated community viremia values as a weighted proportion at the EA level, excluding those classified as recently infected. Significant migrants were those who had lived outside their current region or away from home >one month in the past three years. Recent cross-community in-migrants were those who had moved to the community <two years ago. Separate analyses were done to compare significant migrants to non-migrants and recent cross-community in-migrants to those who in-migrated >two years ago to determine the association of migration and timing with recent infection or viral load suppression (VLS). All proportions are weighted. Of eligible adults, we had HIV results and migration data on 9,625 (83.9%) of 11,474 women and 7,291 (73.0%) of 9,990 men. Most respondents (62.5%) reported significant migration. Of cross-community in-migrants, 15.3% were recent. HIV prevalence was 12.6% and did not differ by migration status. Population VLS was 77.4%. Recent cross-community in-migration was associated with recent HIV infection (aOR: 4.01, 95% CI 0.99-16.22) after adjusting for community viremia. Significant migration (aOR 0.73, 95% CI: 0.55-0.97) and recent cross-community in-migration (aOR 0.57, 95% CI: 0.35-0.92) were associated with lower VLS, primarily due to lack of awareness of HIV infection. The study was limited by lack of precise data on trajectory of migration. Despite a high population-level VLS, Namibia still has migrant populations that are not accessing effective treatment for HIV. Targeting migrants with effective prevention and testing programs in communities with viremia could enable further epidemic control.
Sections du résumé
BACKGROUND
In the 21st century, understanding how population migration impacts human health is critical. Namibia has high migration rates and HIV prevalence, but little is known about how these intersect. We examined the association between migration and HIV-related outcomes using data from the 2017 Namibia Population-based HIV Impact Assessment (NAMPHIA).
METHODS AND FINDINGS
The NAMPHIA survey selected a nationally representative sample of adults in 2017. All adults aged 15-64 years were invited to complete an interview and home-based HIV test. Recent infection (<130 days) was measured using HIV-1 LAg avidity combined with viral load (>1000 copies/mL) and antiretroviral analyte data. Awareness of HIV status and antiretroviral use were based on self-report and/or detectable antiretrovirals in blood. Viremia was defined as having a viral load ≥1000 copies/mL, including all participants in the denominator regardless of serostatus. We generated community viremia values as a weighted proportion at the EA level, excluding those classified as recently infected. Significant migrants were those who had lived outside their current region or away from home >one month in the past three years. Recent cross-community in-migrants were those who had moved to the community <two years ago. Separate analyses were done to compare significant migrants to non-migrants and recent cross-community in-migrants to those who in-migrated >two years ago to determine the association of migration and timing with recent infection or viral load suppression (VLS). All proportions are weighted. Of eligible adults, we had HIV results and migration data on 9,625 (83.9%) of 11,474 women and 7,291 (73.0%) of 9,990 men. Most respondents (62.5%) reported significant migration. Of cross-community in-migrants, 15.3% were recent. HIV prevalence was 12.6% and did not differ by migration status. Population VLS was 77.4%. Recent cross-community in-migration was associated with recent HIV infection (aOR: 4.01, 95% CI 0.99-16.22) after adjusting for community viremia. Significant migration (aOR 0.73, 95% CI: 0.55-0.97) and recent cross-community in-migration (aOR 0.57, 95% CI: 0.35-0.92) were associated with lower VLS, primarily due to lack of awareness of HIV infection. The study was limited by lack of precise data on trajectory of migration.
CONCLUSIONS
Despite a high population-level VLS, Namibia still has migrant populations that are not accessing effective treatment for HIV. Targeting migrants with effective prevention and testing programs in communities with viremia could enable further epidemic control.
Identifiants
pubmed: 34473757
doi: 10.1371/journal.pone.0256865
pii: PONE-D-21-01183
pmc: PMC8412347
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256865Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25115
pubmed: 30027668
Lancet HIV. 2016 Aug;3(8):e388-e396
pubmed: 27470029
PLoS One. 2013 Jun 18;8(6):e66342
pubmed: 23824635
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):183-187
pubmed: 28628529
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25128
pubmed: 30027600
Int J Infect Dis. 2008 Sep;12(5):519-25
pubmed: 18468468
Lancet HIV. 2016 Aug;3(8):e339-e341
pubmed: 27470023
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237762
PLoS Med. 2020 Feb 25;17(2):e1003037
pubmed: 32097428
Open Forum Infect Dis. 2018 Aug 11;5(9):ofy200
pubmed: 30211248
Nat Commun. 2020 Feb 20;11(1):976
pubmed: 32080169
Lancet HIV. 2020 Mar;7(3):e209-e214
pubmed: 32066532
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Lancet HIV. 2019 Sep;6(9):e613-e622
pubmed: 31422056
AIDS Behav. 2016 Apr;20(4):811-20
pubmed: 26395193
S Afr J Econ. 2008;76(supp1):s52-s74
pubmed: 18815625
Sex Transm Dis. 2002 Jan;29(1):44-9
pubmed: 11773878
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
PLoS Med. 2011 May;8(5):e1001034
pubmed: 21629681
Curr Opin HIV AIDS. 2015 Nov;10(6):430-8
pubmed: 26352396
J Infect Dis. 2012 Aug 15;206(4):543-51
pubmed: 22711905
J Int AIDS Soc. 2018 Jul;21 Suppl 4:e25136
pubmed: 30027588
AIDS. 2016 Aug 24;30(13):2099-105
pubmed: 27163708
Lancet HIV. 2018 Apr;5(4):e181-e189
pubmed: 29490875
Glob Public Health. 2017 Aug;12(8):1033-1050
pubmed: 26313708
Sci Data. 2016 Aug 16;3:160066
pubmed: 27529469
AIDS. 2017 Jan 2;31(1):137-145
pubmed: 27755099
J Int AIDS Soc. 2017 Jun 05;20(1):21590
pubmed: 28605171
Lancet HIV. 2016 Apr;3(4):e183-90
pubmed: 27036994
AIDS Behav. 2012 Aug;16(6):1605-21
pubmed: 22481273
Int Marit Health. 2010;62(4):233-40
pubmed: 21348017